WP
AST.WS

WealthPLAN Partners’s Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) AST.WS Stock Holding History

WealthPLAN Partners’s Portfolio AST.WS Stock Details AST.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-26
Closed -$3 – 1171
2016
Q2 		$3 Buy
+26
New +$14 ﹤0.01% 2575

Other funds holding AST.WS

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $109B AUM 42.89% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

WealthPLAN Partners's AST.WS Position: Q3 2016 in Review

WealthPLAN Partners sold out of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) in Q3 2016, closing a stake of 26 shares — an estimated $3 sold.

WealthPLAN Partners first reported a position in AST.WS in Q2 2016 and held it in 1 quarter. The position peaked at $3 in Q2 2016. 37 funds tracked by Wall St. Rank hold AST.WS as of Q3 2016.

  • WealthPLAN Partners reported no remaining Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position as of Q3 2016 after selling out during the quarter.
  • WealthPLAN Partners sold 26 Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) shares in Q3 2016, an estimated $3.
  • WealthPLAN Partners first reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in Q2 2016 and held it in 1 quarter.
  • WealthPLAN Partners's Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position peaked at $3 in Q2 2016.
  • 37 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) as of Q3 2016.

Based on WealthPLAN Partners's 13F filing for Q3 2016, filed 9 Dec 2016.